Inside informationEnglish
Press Release: ACAAI: Sanofi and Regeneron’s Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority review
The file is served by the AMF. We do not host a copy.
Document type
- Issuer
- Sanofi
- Filed
- 07/11/2025, 14:00
- Document type
- Inside information
- AMF sub-type
- Informations privilégiées
- Language
- English
- AMF reference
- 117611_20251107